This study evaluates the cost-effectiveness of talazoparib vs. the physician’s choice of chemotherapy as maintenance therapy for germline BRCA1/2 mutated HER2-negative advanced breast cancer from the perspective of healthcare in China and the US. This evidence concerns the gene BRCA1 and breast carcinoma.